CAT/Abbott's D2E7 in Crohn's disease trials
Abbott Laboratories of the USA has said that the potential rheumatoidarthritis drug D2E7 is now in intermediate Phase II clinical trials to assess its activity against Crohn's disease, reports Reuters. Abbott will gain the rights to the drug along with its in-progress $6.9 billion acquisition of BASF's pharmaceutical operations (Marketletter January 1 & 8 and page 5 this issue). The latter was co-developing D2E7 with UK-based Cambridge Antibody Technology.
D2E7 is currently in final Phase III testing for rheumatoid arthritis, an indication for which it is likely to reach the market in 2003. Analysts reported by the news agency, suggest the product could have annual sales of $500 million or more. If successful, D2E7 for the Crohn's indication could follow some time after that.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze